BOYDSense

Health monitoring made simple - powered by breath

BOYDSense, an award winning and pioneering healthtech company redefining how the world monitors and manages metabolic health. Our unique breakthrough platform uses breath analysis - not needles - to track glucose ranges and Ketones for additional metabolic insights. With a single, pain-free breath sampling, we give healthy people, people with pre-diabetes and early-stage Type 2 diabetes the ability to take control of their health, weight, diet, and lifestyle in a way that’s simple, engaging, and actionable.

The opportunity is massive: over 1 billion people are underserved today because existing tools are invasive, only clinical, and off-putting. BOYDSense changes that.

Two-device roadmap:

Consumer launch with partners end 2026 → health enthusiasts and weight-conscious users who like to get a unique biomarker for preventative health.

Medical launch in 2028 → pre-diabetics and early-stage Type 2 (non-insulin).

Proven science & IP: 4 clinical trials, 30 years of volatile organic compounds (VOC) expertise, 9 patent families.

Experienced team: Multiple successful product launches and exits (>$550M).